September 14, 2015 — ImaginAb Inc. has released interim results from a Phase 2 clinical trial of IAB2M, the company's proprietary imaging agent for management of prostate cancer. IAB2M demonstrated superior performance in detecting disease compared with ProstaScint and conventional imaging technologies including computed tomography (CT) scans, magnetic resonance imaging (MRI) scans and bone scans. In addition, the agent accurately detected metastatic disease in normal-sized lymph nodes, overcoming a major limitation of existing technologies and addressing a key clinical need.
The trial data were presented at the World Molecular Imaging Congress 2015 in Honolulu, Hawaii.
"Accurate detection of extra-prostatic disease in high-risk prostate cancer is critical for providing the best possible care to patients undergoing radical prostatectomy," said Robert Reiter, M.D., co-director of the Genitourinary Oncology Program in UCLA's Jonsson Cancer Center. "However, conventional imaging fails to detect metastatic disease in up to 50 percent of high-risk prostate cancer patients. As our data show, ImaginAb's imaging agent provides a whole-body picture of disease activity, with the potential to change patient management and guide the course of care for best possible outcomes."
Results include the first nine of 20 patients in an ongoing, open-label, Phase 2, single-center trial. Patients received IAB2M intravenously prior to a whole-body positron emission tomography (PET) scan. The agent detected disease in lymph nodes of three of six subjects, later confirmed positive for metastasis at surgery. This is in stark contrast to ProstaScint and conventional imaging, which did not detect metastasis in lymph nodes in any of those subjects.
For more information: www.imaginab.com
July 30, 2024 
